Sodium butyrate enhances the cytotoxic effect of antineoplastic drugs in human lymphoblastic T-cells.
Sodium butyrate (NaB), a potent histone deacetylase inhibitor, induces cell cycle arrest and apoptosis in malignant cells. We investigated the effects on cellular proliferation in vitro when combining NaB with antineoplastic drugs commonly used to treat leukemias. Our results demonstrate that NaB increases the cytotoxic effects of cytarabine and etoposide, but not of bleomycin, doxorubicin, vincristine or methotrexate. These data suggest that NaB is a promising adjuvant therapeutic agent for the treatment of lymphoblastic leukemias, and provides a basis for further studies in this field.
dos Santos
M P
MP
Cancer Research Laboratory, Academic Hospital Research Center, Federal University of Rio Grande do Sul, 90035-903 Porto Alegre, RS, Brazil.
Schwartsmann
G
G
Roesler
R
R
Brunetto
A L
AL
Abujamra
A L
AL
D000970:Antineoplastic Agents / Q000494:pharmacology*; D001761:Bleomycin; D002087:Butyrates / Q000494:pharmacology*; D049109:Cell Proliferation / Q000187:drug effects; D003561:Cytarabine; D004317:Doxorubicin; D004357:Drug Synergism; D005047:Etoposide; D006801:Humans; D019169:Jurkat Cells; D015458:Leukemia, T-Cell / Q000188:drug therapy* / Q000473:pathology; D008727:Methotrexate; D013601:T-Lymphocytes / Q000187:drug effects* / Q000473:pathology; D014750:Vincristine
D000970:Antineoplastic Agents; D002087:Butyrates; D003561:Cytarabine; D001761:Bleomycin; D014750:Vincristine; D005047:Etoposide; D004317:Doxorubicin; D008727:Methotrexate